Abbott Laboratories

ABT.US Weekly Report · 2026-W34

Abbott Laboratories gained 4.84% this week, closing at $116.64. The key contradiction lies in valuation reaching a 5-year low (PE at only 3rd percentile) while the institutional base remains bullish, yet Q2 earnings revealed core profitability collapsing (EPS down 47.5% YoY). The infant formula litigation settlement reduces near-term legal drag, and diagnostics expansion accelerates, but uncertainty over the earnings inflection point dominates investor sentiment. Institutional distribution is evident amid cautious capital flows.

Trading Activity

The stock rose from $110.37 (Monday close) to $116.64 (Friday), a weekly gain of 4.84%. Intra-week high reached $116.66, low $109.35, for an amplitude of 6.68%. The advance was gradual through Wednesday (1-2% daily moves) before accelerating on Friday (+2.19%). Volume remained steady at an average 9.88M shares daily, showing no unusual spike.

Valuation and Earnings

Current PE stands at 37.61x, PB at 3.97x. Historically, PE is at approximately the 3rd percentile over 5 years—an extreme low. Yet a stark contradiction emerges on the profit front:

Q2 2026 reported EPS of $0.53 (down 47.5% YoY), operating revenue of $12.593B (up 13.0% YoY), net profit of $928M (down 47.8% YoY), and net margin compressed to 7.37% (from 9.65% in Q1 and 15.50% in Q4). This “growing revenue, shrinking profit” pattern reflects cost headwinds, including the $670M settlement accrual and Exact Sciences integration expenses.

Consensus projects $5.80 EPS for FY 2026. Q2 accounts for merely 9% of that target, implying the remaining quarters must deliver substantially stronger results. The ultra-low valuation may not yet have fully priced in the earnings deterioration risk.

Capital Flows

Large institutional investors showed net outflows of $7.962B ($1.663B in, $9.623B out), while retail held closer to equilibrium (net outflows of $270M). The divergence—institutions aggressively exiting, retail moderately holding—reflects institutional concern over the profit inflection point at this depressed price level.

Institutional Commentary

28 analysts cover the name: 17 Buy (60%), 6 Hold, 1 Neutral, 4 Reduce. Median price target is $120.20, implying 3.1% upside. However, these ratings have not been refreshed in over three weeks since the Q2 earnings release, so a reversion is likely.

This Week’s News

Litigation Settlement and Cost Release: Abbott resolved infant formula preterm infant litigation for $670M, with the charge absorbed in Q2 earnings, clearing pressure for subsequent quarters.

Diagnostics Acceleration: An analyst raised the price target to $135, citing strengthening cancer diagnostics capabilities (Exact Sciences integration success). Multi-year collaboration with HealthTab in the UK expands point-of-care testing footprint, signaling diagnostics as the growth pillar.

Key stories:

• Abbott Laboratories Stock Outperforms Competitors On Strong Trading Day
• Jefferies Sticks to Their Buy Rating for Abbott Laboratories (ABT)
• Analyst Raises Abbott Price Target to $135 on Strengthening Cancer Diagnostics Growth and Successful Exact Sciences Integration
• Abbott Bypasses Appeals Process To Settle Ongoing Premature Infant Formula Litigation
• Wells Fargo Keeps Their Buy Rating on Abbott Laboratories (ABT)
• Abbott agrees to $670 million settlement of infant formula cases
• HealthTab™ Enters Multi-Year Collaboration Agreement with Abbott for Point-of-Care Testing Across the UK
• Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare

Contradictions and Observations

Three data streams point in conflicting directions:

1. Valuation vs. Earnings Disconnect: Ultra-low PE (5-year 3rd percentile) typically signals attractive pricing, but Q2 EPS down nearly 50% YoY breaks that thesis. The extreme valuation may not yet price the full scope of earnings compression.

2. Analyst Ratings vs. Capital Flows: 60% buy ratings and 3.1% consensus upside clash with sharp institutional selling, suggesting ratings lag behind capital markets’ risk reassessment.

3. Single Quarter vs. Full-Year Tension: Q2 EPS covers just 9% of the FY consensus target. Subsequent quarters must perform substantially better to hit the year estimate, introducing acute execution uncertainty that institutional exits acknowledge.

The stock trades as a price-cheap story hindered by deteriorating fundamentals. Valuations are compelling, institutional analysts mostly positive, yet large institutions are voting “no” through their actions. The next critical inflection is whether Q3-Q4 earnings prove Q2 was a trough or evidence of a profitability reset.